Publications by authors named "A Arance"

Claim this Profile
R
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.
A Arance, M-A Berciano-Guerrero, J Guo, M S Carlino, P A Ascierto

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events.
Gary Amseian, Francisco Aya, Camilo Pineda, Sofía González-Ortiz, Juan-Andrés Mora, Ana Arance

Insights Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.
Clara Martínez-Vila, Cristina Teixido, Roberto Martín, Francisco Aya, Sumedha Sudhaman, Ana Arance

Cancers (Basel)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
E Seguí, F Brasó-Maristany, T Pascual, E Sanfeliu, I Victoria, A Arance

ESMO Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana M Arance

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis